GlassScriptPhysician profile
Laila Rahbar
NPI 1417140864
$2,802.50
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $96.43 · 2021: $497 · 2022: $528 · 2023: $465 · 2024: $325 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.31 |
| Education | $127.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $814.16 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $320.17 | 2019-2023 | |
| Glaxosmithkline, LLC. | $262.10 | 2020-2022 | |
| Janssen Biotech, INC. | $226.06 | 2019-2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $186.83 | 2021-2024 | Saphnelo |
| Lilly USA, LLC | $185.46 | 2019-2024 | Taltz |
| Pfizer INC. | $168.56 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $92.47 | 2019 | |
| Radius Health, INC. | $86.16 | 2019-2024 | Tymlos |
| Fidia Pharma USA INC. | $81.79 | 2022-2025 | Hymovis, Triluron, Hyalgan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.70 | 2019-2024 | Ofev |
| Celgene Corporation | $61.73 | 2019-2024 | Orencia |
| Novartis Pharmaceuticals Corporation | $44.11 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $41.41 | 2021-2025 | Lupkynis |
| Ucb, INC. | $38.88 | 2021-2024 | Bimzelx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.55 | 2019-2024 | Actemra |
| Regeneron Healthcare Solutions, INC. | $24.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.81 | 2025 | Orencia |
| Sandoz INC. | $19.44 | 2025 | Hyrimoz |
| Horizon Therapeutics Plc | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laila Rahbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.